{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:57:20Z","timestamp":1758632240888,"version":"3.44.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1053\/j.seminhematol.2013.11.006","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T10:18:25Z","timestamp":1384424305000},"page":"17-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Chemotherapeutic Advancements in Peripheral T-Cell Lymphoma"],"prefix":"10.1053","volume":"51","author":[{"given":"Nishitha M.","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2013.11.006_bib1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/asheducation-2008.1.280","article-title":"Prognosis and primary therapy in peripheral T-cell lymphomas","author":"Savage","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib2","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.6004\/jnccn.2013.0037","article-title":"Non-Hodgkin's lymphomas, version 1.2013","volume":"11","author":"Zelenetz","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib5","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib6","first-page":"2728a","article-title":"Survival of newly diagnosed T-cell lymphoma (TCL) in the modern era: investigation of prognostic factors with critical examination of therapy in a multicenter US cohort","volume":"120","author":"Evens","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2013.11.006_sbref7","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2003-05-1675","article-title":"Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients","volume":"102","author":"Belhadj","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.006_sbref7a","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","article-title":"How I treat prolymphocytic leukemia","volume":"120","author":"Dearden","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib8","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","article-title":"Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma","volume":"20","author":"Gisselbrecht","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib10","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2003-02-0542","article-title":"Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma","volume":"102","author":"Tilly","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000093637","article-title":"Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study","volume":"116","author":"Yamazaki","year":"2006","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib12","first-page":"401","article-title":"Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-Cell lymphomas (PTCL)\u2014a phase II study of the Nordic Lymphoma Group (NLG)","volume":"108","author":"d'Amore","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1365-2141.2011.08634.x","article-title":"Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers","volume":"153","author":"Niitsu","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib15","first-page":"943","article-title":"[Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen]","volume":"23","author":"Peng","year":"2004","journal-title":"Ai Zheng"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib16","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience","volume":"103","author":"Escalon","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib17","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib18","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib19","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1001\/jama.2008.585","article-title":"Anaplastic large-cell lymphoma in women with breast implants","volume":"300","author":"de Jong","year":"2008","journal-title":"JAMA"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib20","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1097\/PRS.0b013e3182172418","article-title":"Anaplastic large cell lymphoma and breast implants: a systematic review","volume":"127","author":"Kim","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib21","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2141.2001.02794.x","article-title":"Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients","volume":"113","author":"Matutes","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.thj.6200195","article-title":"A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia\/lymphoma","volume":"3","author":"Hermine","year":"2002","journal-title":"Hematol J"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib24","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1182\/blood-2009-03-211821","article-title":"Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia\/lymphoma (ATL)","volume":"113","author":"Kchour","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/00000478-199807000-00010","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha\/beta and gamma\/delta subtypes","volume":"22","author":"Salhany","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1046\/j.1365-2133.2003.05226.x","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients","volume":"148","author":"Hoque","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib27","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib28","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archderm.136.7.889","article-title":"Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases","volume":"136","author":"Marzano","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib30","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1365-2133.2010.09951.x","article-title":"Subcutaneous panniculitis-like T-cell lymphoma alphabeta: complete sustained remission with corticosteroids and methotrexate","volume":"163","author":"Briki","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib31","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1200\/JCO.2000.18.4.795","article-title":"Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center","volume":"18","author":"Gale","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib32","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2012-11-466839","article-title":"Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT","volume":"121","author":"Jantunen","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib33","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdn751","article-title":"Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment","volume":"20","author":"Falchook","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib34","first-page":"90","article-title":"Pentostatin (2'-deoxycoformycin) for the treatment of hepatosplenic gammadelta T-cell lymphomas","author":"Corazzelli","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib35","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1046\/j.1365-2141.2002.03537_3.x","article-title":"Hepatosplenic gammadelta T-cell lymphoma: complete response induced by treatment with pentostatin","volume":"117","author":"Iannitto","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/10428190109099342","article-title":"2'-Deoxycoformycin for hepatosplenic gammadelta T-cell lymphoma","volume":"42","author":"Grigg","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib37","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/annonc\/mdn119","article-title":"Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine","volume":"19","author":"Jaeger","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-0609.2006.00646.x","article-title":"A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab","volume":"76","author":"Mittal","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib39","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1080\/10428190310001609924","article-title":"Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha\/beta hepatosplenic T-cell non-Hodgkin's lymphoma","volume":"45","author":"Chanan-Khan","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2012.09.002","article-title":"Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience","volume":"13","author":"Voss","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib41","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","article-title":"Treatment of refractory T-cell malignancies using gemcitabine","volume":"113","author":"Sallah","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib43","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3109\/10428194.2012.739286","article-title":"Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma","volume":"54","author":"Yao","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib44","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cncr.27733","article-title":"Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350","volume":"119","author":"Mahadevan","year":"2013","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib46","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib47","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3109\/10428194.2012.742521","article-title":"A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study","volume":"54","author":"Foss","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib48","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/bjh.12488","article-title":"A phase I\/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas","volume":"163","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib50","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"year":"2013","series-title":"The novel 2nd generation proteasome inhibitor MLN9708 induces redox and MAPK-dependent cell death in T-cell lymphoma (TCL) and Hodgkin lymphoma (HL) cell lines and human lymphoma xenograft models","author":"Dashnamoorthy","key":"10.1053\/j.seminhematol.2013.11.006_bib51"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib52","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib53","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib54","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3109\/10428194.2011.623256","article-title":"Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial","volume":"53","author":"Advani","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2013.11.006_bib55","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719631300156X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719631300156X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:22:35Z","timestamp":1758522155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719631300156X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S003719631300156X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2013.11.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapeutic Advancements in Peripheral T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2013.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}